Edition:
United States

Diffusion Pharmaceuticals Inc (DFFN.OQ)

DFFN.OQ on NASDAQ Stock Exchange Capital Market

0.55USD
20 Apr 2018
Change (% chg)

$-0.02 (-3.16%)
Prev Close
$0.57
Open
$0.58
Day's High
$0.58
Day's Low
$0.55
Volume
15,704
Avg. Vol
152,693
52-wk High
$3.93
52-wk Low
$0.50

Chart for

About

Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC)... (more)

Overall

Beta: -0.90
Market Cap(Mil.): $28.29
Shares Outstanding(Mil.): 50.53
Dividend: --
Yield (%): --

Financials

  DFFN.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -0.32 -- --
ROI: -13.50 -0.74 13.19
ROE: -24.44 -2.80 15.00

BRIEF-Diffusion Pharmaceuticals Files Prospectus Related To Offering Of Common Stock

* DIFFUSION PHARMACEUTICALS INC FILES PROSPECTUS RELATED TO OFFERING UP TO 12.3 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING‍​ Source text: (http://bit.ly/2nGHE9Q) Further company coverage:

Feb 06 2018

BRIEF-Diffusion Pharmaceuticals Announces $12 Mln Underwritten Public Offering

* DIFFUSION PHARMACEUTICALS ANNOUNCES $12 MILLION UNDERWRITTEN PUBLIC OFFERING

Jan 18 2018

BRIEF-Diffusion Pharmaceuticals Begins Phase 3 Clinical Trial With TSC In Glioblastoma Multiforme

* DIFFUSION PHARMACEUTICALS BEGINS PHASE 3 CLINICAL TRIAL WITH TSC IN GLIOBLASTOMA MULTIFORME

Dec 27 2017

BRIEF-Diffusion Pharma Files For Stock Offering For Up To About $15 Mln

* DIFFUSION PHARMACEUTICALS FILES FOR STOCK OFFERING FOR UP TO ABOUT $15 MILLION - SEC FILING Source text for Eikon: (http://bit.ly/2BbtOBi) Further company coverage:

Dec 20 2017

Earnings vs. Estimates